Surgical Outcomes in Macular Telangiectasia Type 2-Related Macular Holes: A Report on Four Patients

Table 1

Summary table of patient characteristics, surgical methods, and outcomes of patients with FTMH associated with MacTel Type 2.

	Case 1 OD	Case 1 OS	Case 2 OD	Case 3 OS	Case 4 OD
Age (years)	62	62	71	65	57
Gender	Female	Female	Male	Female	Female
Preoperative BCVA	20/80	20/80	20/50	20/200	20/60
Time from symptom onset to surgery	1 month	3 months	4 months	9 months	Unknown
Macular hole size (μm)
Diameter	410	246	225	184	493
Maximum height	426	424	340	403	309
Posterior vitreous detachment	Yes	Yes	No	No	No
Surgical procedure	PPV, ICG-assisted ILM peeling, cataract surgery done at the time of PPV	PPV, ICG-assisted ILM peeling, cataract surgery done at the time of PPV	PPV, ICG-assisted ILM peeling	PPV, ICG-assisted ILM peeling	PPV, ICG-assisted ILM peeling, cataract surgery done 1 month prior to PPV
Tamponading agent	30% SF6	30% SF6	30% SF6	30% SF6	15% C3F8
Positioning, duration	Prone, 1 week	Prone, 1 week	Prone, 1 week	Prone, 1 week	Prone, 1 week
Anatomical hole closure	Closed hole	Closed hole	Closed hole	Closed hole	Not closed
EZ and ELM integrity on most recent OCT	Yes	Yes	Yes	Yes	No
BCVA at last follow-up	20/25	20/20	20/20-1	20/40-1	20/60
Length of follow-up	26 months	37 months	21 months	35 months	22 months

PPV: pars plana vitrectomy; ILM: internal limiting membrane; ICG: indocyanine green; EZ: ellipsoid zone; ELM: external limiting membrane; BCVA: best corrected visual acuity; SF₆: sulfur hexafluoride; C₃F₈: perfluoropropane.